ecancermedicalscience

Research

Is there a role for 'modified VAD' in the treatment of multiple myeloma?

4 Jun 2009
A Agazzi, S Sammassimo, D Laszlo, SJ Liptrott, R Cascio, A Alietti, C Rabascio, P Mancuso, G Pruneri, G Martinelli

VAD, (Vincristine, Doxorubicin and Dexamethasone) was initially proposed as a salvage therapy for myeloma patients in whom prior alkylating agent therapy failed, although in recent years VAD has been surpassed by novel combination therapies with new biological agents such as thalidomide (and its derivative, lenalidomide) and bortezomib. After the excellent results obtained by the novel agents, VAD can no longer be proposed in preparation to autologous transplantation, although there are still indications that VAD remains useful and clinically relevant in the initial treatment of symptomatic multiple myeloma.

Related Articles

Amanda Acioli de Almeida Robatto, Erika Andrade Rocha, Renata Colombo Bonadio, Denis Artico Galhera, Carolina Teixeira Muratori, Admir Andre Belo Bueno, Abraão Ferreira Lopes Dornellas, Luciana Bastos Valente Alban, Carolina Ribeiro Victor, Maria Ignez Freitas Melro Braghiroli, Marília Polo Mingueti e Silva, Camila Soares Araujo, Carlos Frederico Sparapan Marques, Caio Sergio Rizkallah Nahas, Karim Yaqub Ibrahim, André Tsin Chih Chen, Paulo Marcelo Gehm Hoff, Camila Motta Venchiarutti Moniz
Joaquin Fernandez-Alberti, Alex R Villaalta López, Guillermo Scolari, Alejandro Iotti, Marcelo Featherston
Jessica J Farzan, Jiddu Guart, Gabriel De la Cruz Ku, Nichita Kulkarni, Rachel Huselid, Anshumi Desai, Camila Franco, Vanessa Mroueh, Jessica Mroueh, Gonzalo Ziegler
Agodirin Olayide, Chijioke Chijindu, Mustapha Fathi, Rahman Ganiyu, Olatoke Samuel, Olaogun Julius, Akande Halima